Achieve Life Sciences (ACHV) Short term Debt (2016 - 2025)

Achieve Life Sciences has disclosed Short term Debt across 5 years of filings, most recently posting $3.7 million for Q4 2025.

• Quarterly Short term Debt changed N/A year-over-year to $3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.7 million (changed N/A YoY) and the FY2025 annual result came in at $3.7 million, changed N/A from the prior year.
• Short term Debt climbed to $3.7 million in Q4 2025, from $1.2 million in the prior quarter.
• Over five years, Short term Debt peaked at $17.1 million in Q1 2024 and troughed at $528000.0 in Q4 2023.
• A 4-year average of $7.4 million and a median of $3.7 million in 2025 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2023 — Short term Debt slumped 96.71% — and 2024, when it grew 4.7%.
• Tracing ACHV's Short term Debt over 4 years: stood at $16.1 million in 2022, then sank by 96.71% to $528000.0 in 2023, then jumped by 1567.42% to $8.8 million in 2024, then tumbled by 57.93% to $3.7 million in 2025.
• Business Quant data shows ACHV's Short term Debt at $3.7 million in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.